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Renal actions of synthetic Dendroaspis natriuretic peptide. natriuretic peptide A-receptor (NPR-A), which, via 3959-
Background. Dendroaspis natriuretic peptide (DNP), re- cyclic guanosine monophosphate (cGMP), mediate the
cently isolated from the venom of the green Mamba snake biological actions of natriuresis, vasodilation, renin inhi-Dendroaspis angusticeps, is a 38 amino acid peptide containing
bition, and lusitropism [3–5]. CNP lacks renal actions, buta 17 amino acid disulfide ring structure similar to that of atrial
is vasodilating and growth inhibiting [2, 6]. CNP mediatesnatriuretic peptide (ANP), brain natriuretic peptide (BNP),
and C-type natriuretic peptide (CNP). DNP-like immunoreac- its actions through the natriuretic peptide b-receptor
tivity (DNP-LI) was reported to be present in human plasma (NPR-B), which is also linked to particulate guanylyl
and atrial myocardium and to be elevated in human congestive cyclase and cGMP generation [7]. Although this familyheart failure. Although previously named DNP, it remains un-
of peptides now consists of three known peptides, theknown if DNP is natriuretic or if is it present in canine plasma,
discovery of additional genes encoding putative guanylylurine, and atrial myocardium.
Method. Studies were performed in vivo in anesthetized cyclases has raised the question about the possible exis-
dogs (N 5 6) using intravenous infusion of synthetic DNP tence of numerous ligands for these receptors yet to be
at 10 and 50 ng/kg/min. Employing a sensitive and specific discovered in mammal species [8]. Recently, additional
radioimmunoassay for DNP, the presence of DNP-like peptide
natriuretic peptides have been isolated and character-was assessed in the canine plasma and urine before, during,
ized, particularly from the venom of the snakes Dendro-and following the administration of exogenous synthetic DNP.
Additionally, we performed immunohistochemical studies us- aspis angusticeps, Micrurus corallinus, and Bothrops jara-
ing the indirect immunoperoxidase method with polyclonal raca [9–11]. The physiological role of these peptides, as
DNP antiserum in normal atrial myocardium (N 5 10). Atrial well as their presence in other species, remains unclear.
concentrations of DNP-LI were also assessed.
One of these newly characterized peptides possessingResults. We report that DNP is markedly natriuretic and
a structural similarity to the natriuretic peptide family,diuretic, which, like ANP and BNP, is associated with the in-
which was isolated from the venom of Dendroaspis an-crease in urinary and plasma cGMP. DNP-like peptide is also
detected in canine plasma, urine, and atrial myocardium. gusticeps, or green Mamba snake [9], is a 38-amino acid
Conclusion. These studies establish that DNP is a potent peptide containing a 17-amino acid disulfide ring struc-
natriuretic and diuretic peptide with tubular actions linked to ture with a 15-residue C terminal extension (Fig. 1). ThiscGMP and that DNP may play a physiological role in the
peptide potently vasorelaxes isolated rodent aorta [9]regulation of sodium excretion.
and canine coronary arteries with comparable potency
to ANP (abstract; Wennberg and Burnett, J Am Coll
Cardiol 29:305A, 1997). Additionally, this peptide aug-Investigations have established the existence of a fam-
ments the formation of cGMP in aortic endothelial andily of structurally similar but genetically distinct natri-
smooth muscle cells and displaces ANP binding fromuretic peptides that consist of atrial natriuretic peptide
the natriuretic peptide receptors [9]. Most recently, we(ANP) and brain natriuretic peptide (BNP) of myocar-
have reported that Dendroaspis natriuretic peptidedial cell origin, and C-type natriuretic peptide (CNP) of
(DNP)-like immunoreactivity (DNP-LI) is present in hu-endothelial cell origin [1, 2]. ANP and BNP bind to the
man plasma and atrial myocardium and is elevated in
the plasma of humans with congestive heart failure [12].
We also determined that DNP levels in normal humanKey words: myocardium, natriuretic hormones, cGMP, sodium excre-
tion, Dendroaspis angusticeps. plasma averaged 6 pg/ml with a range from 2 to 11 pg/ml.
In human congestive heart failure (New York HeartReceived for publication December 1, 1998
Association guidelines; NYHA III or IV), we reportedand in revised form March 9, 1999
Accepted for publication March 16, 1999 that DNP plasma levels averaged 37 pg/ml with a range
from 3 to 200 pg/ml. 1999 by the International Society of Nephrology
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were anesthetized with pentobarbital sodium given intra-
venously (30 mg/kg). Supplemental nonhypotensive
doses of pentobarbital sodium were given as needed
during the experiment. After tracheal intubation, dogs
were mechanically ventilated (Harvard respirator; Har-
vard Apparatus, Millis, MA, USA) with 4 liter/min of
supplemental oxygen.
Left lateral flank incisions were made, and the left
kidney was exposed via a retroperitoneal approach. The
ureter was cannulated with polyethylene catheters (PE-
200) for a timed urine collection, and a calibrated non-
cannulating electromagnetic flow probe was placed care-
fully around the left renal artery and connected to a
flowmeter (model FM 5010, Carolina Medical Electron-
ics, King, NC, USA) for continuous monitoring of renal
blood flow (RBF). Finally, the right femoral vein was
cannulated with two polyethylene catheters (PE-240),
one for infusion of inulin and the other for the infusion
of DNP (DNP 1-38; Phoenix Pharmaceuticals, Inc.,
Mountain View, CA, USA). The right femoral artery
was cannulated with a polyethylene catheter (PE-240)
for direct arterial blood pressure measurement and arte-
rial blood sampling.
After completion of the surgical preparation, a prim-
ing dose of inulin (ICN Biomedicals, Cleveland, OH,Fig. 1. Amino acid sequence and structure of Dendroaspis natriuretic
peptide. The amino acid sequence was originally reported by Schweitz USA) dissolved in isotonic saline solution was injected,
et al [9]. followed by a constant infusion of 1 ml/min to achieve
a steady-state plasma inulin concentration between 40
and 60 mg/dl. The dogs were placed in dorsal suspension
and allowed to equilibrate for 60 minutes without inter-Although this peptide, based on its structural similarity
vention. Body temperature was maintained by externalto ANP, BNP, and CNP, was named DNP, it remains
warming (infrared heating lamp).unknown if DNP is natriuretic. Indeed, the renal actions
After an equilibration period of 60 minutes, a 30-of DNP are undefined.
minute baseline clearance (baseline) was performed. ThisBased on the structural similarity to the other natri-
was followed by a 15-minute lead-in period, during whichuretic peptides and the report that DNP activates cGMP
DNP infusion at 10 ng/kg/min was begun intravenously,in vitro, we hypothesized that DNP is a natriuretic and
after which the second 30-minute clearance (DNP-10)diuretic peptide. We therefore investigated the renal ac-
period was performed. After the second clearance pe-tions of synthetic DNP in vivo in normal anesthetized
riod, the intravenous infusion of DNP was changed todogs. We also determined whether or not DNP-LI is
50 ng/kg/min. After a 15-minute lead-in period with thispresent in canine plasma, urine, and atrial myocardium.
dose of DNP, a 30-minute clearance (DNP-50) was per-
formed. At the end of the third clearance, the DNP
METHODS infusion was stopped and a 150-minute washout period
followed with a 30-minute recovery clearance (recovery).Studies were performed in six male mongrel dogs
weighing between 20 and 25 kg. Dogs were maintained
Analytical methodson a normal-sodium diet with standard dog chow (Lab
Canine Diet 5006; Purina Mills, St. Louis, MO, USA) Plasma for electrolyte and inulin measurements was
obtained from blood collected in heparinized tubes.with free access to tap water. All studies conformed to
the guidelines of the American Physiological Society and Plasma and urine electrolytes including lithium were
measured by flame-emission spectrophotometer (IL943,were approved by the Mayo Clinic Animal Care and
Use Committee. Flame Photometer; Instrumentation Laboratory, Lex-
ington, MA, USA). Plasma and urine inulin concentra-On the evening before the experiment, 300 mg of
lithium carbonate were administered orally for the as- tions were measured by the anthrone method, and the
glomerular filtration rate (GFR) was measured by thesessment of renal tubular function, and dogs were fasted
overnight. On the day of the acute experiment, all dogs clearance of inulin. The lithium clearance technique was
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employed to estimate the proximal and distal fractional employing the same sensitive and specific radioimmuno-
assay.reabsorption of sodium. Proximal fractional reabsorp-
tion was calculated by the following formula: [1 2 (lith-
Immunohistochemical methodsium clearance/GFR)] 3 100. Distal fractional reabsorp-
tion of sodium was calculated by this formula: [(lithium Sections for immunohistochemical staining were taken
from atrial free walls from 10 normal dogs not exposedclearance 2 sodium clearance)/lithium clearance] 3 100.
Plasma and urinary cGMP were measured by radioim- to exogenous DNP. Immunohistochemical studies were
performed by the indirect immunoperoxidase method asmunoassay using the method of Steiner, Parker, and
Kipnis [13]. Urine for cGMP measurement was heated described previously [14]. Tissues were immediately fixed
with 10% buffered formalin and were embedded in par-to 908C before storage at 2208C to inhibit degradative
enzymatic activity. affin, and sections 6 mm thick were cut and mounted on
salinized glass slides. The sections were deparaffinizedPlasma and urinary DNP-LI was determined using a
specific and sensitive radioimmunoassay for DNP before, with graded concentrations of xylene and were hydrated
with ethanol. To block the activity of endogenous peroxi-during, and following the DNP administration. Blood
was collected in chilled tubes containing ethylenedi- dase, the slides were incubated with 0.6% hydrogen per-
oxide in methanol for 20 minutes at room temperature.aminetetraacetic acid (EDTA) and immediately placed
on ice. After centrifugation at 2500 r.p.m. at 48C for 10 After being washed, sections were incubated in 5% nor-
mal goat serum (Dako, Carpinteria, CA, USA) for 10minutes, the plasma was decanted and stored at 2208C
until analyzed. Plasma (1 ml) was extracted on C-8 Bond minutes at room temperature to reduce nonspecific back-
ground staining and were then incubated with polyclonalElut cartridges, which were washed with methanol and
distilled water. DNP was eluted with 95% methanol con- rabbit anti-DNP (Phoenix Pharmaceuticals) at a dilution
of 1:500 (in normal goat serum) in humidified chamberstaining 1% trifluoroacetic acid (TFA). Concentrated
elutes were then assayed with a specific and sensitive for 18 hours at room temperature. All slides were incu-
radioimmunoassay for DNP (Phoenix Pharmaceuticals). bated for 30 minutes with the second antibody-horserad-
Urinary DNP-LI was measured directly by this radioim- ish peroxidase conjugate (BioSource, Camarillo, CA,
munoassay without extraction. Samples and standards USA). The reaction was visualized by incubating the
were incubated with rabbit anti-DNP at 48C for 18 hours. sections with a solution of 39-amino-99-ethylcarbazole
125I-labeled DNP (100 ml) was added and incubated for (Sigma, St. Louis, MO, USA) in dimethylformamide and
another 18 hours at 48C. Free and bound fractions were sodium acetate. The sections were counterstained with
then separated by the addition of a second antibody/ hematoxylin and were coverslipped and reviewed with
normal rabbit serum solution and were centrifuged. Ra- an Olympus microscope. Control sections were stained
dioactivity of the bound fraction was measured with a g with 1% nonimmune goat serum. Specificity of immuno-
counter. The minimal detectable level for this assay was staining was confirmed by adsorption testing.
0.5 pg per tube, and the IC50 of the standard curve was
Statistical analysis29.0 pg. Recovery was 83.0 6 1.8%, and the intra-assay
coefficient of variation (CV) was 10.0 6 1.8% and in- Results of quantitative studies are expressed as mean 6
terassay CV was 12.0 6 1.5%. There was no cross-reac- se. Statistical comparisons were performed using re-
tivity between the DNP assay and the ANP, BNP, or peated-measures analysis of variance, followed by the
CNP assays. We challenged the DNP radioimmunoassay post hoc Bonferroni test. Statistical significance was ac-
with increasing concentrations of ANP, BNP, and CNP cepted for a P value of less than 0.05.
over a range from 0.5 to 500 pg while also challenging
the ANP, BNP, and CNP assay with increasing concen-
RESULTStrations of DNP over a range from 0.5 to 500 pg. We
Plasma DNP and urinary DNP excretion are showndetected no cross-reactivity between the ANP, BNP,
in Figure 2. Employing the specific and sensitive radioim-CNP, and DNP assays. The second methodology, which
munoassay, plasma and urinary DNP-LI were detectablewas used to test the specificity of the radioimmunoassay
prior to infusion of exogenous DNP. Both plasma andfor DNP, was immunoblotting. Immunoblotting was per-
urinary DNP excretion increased during DNP infusionformed employing antibodies to DNP using synthetic
and decreased during the recovery period.ANP, BNP, CNP, and DNP at the concentrations of 100,
Urinary sodium excretion (UNaV), urine flow (UV),10, 1, and 0.1 ng, with no cross-reactive staining for ANP,
plasma cGMP, and urinary cGMP excretion (UcGMPV) inBNP, or CNP. Positive and dose-dependent immuno-
response to exogenous DNP are illustrated in Figure 3.staining was noted with the DNP antibody at concentra-
Low-dose DNP (10 ng/kg/min) increased UNaV in associ-tions of DNP at 100, 10, and 1 ng.
ation with increases in plasma cGMP and UcGMPV. High-Atrial tissue concentration of DNP-LI was determined
in the 10 normal dogs not exposed to DNP infusion dose DNP (50 ng/kg/min) further increased UNaV with a
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Fig. 2. Plasma Dendroaspis natriuretic pep-
tide (PDNP; A) and urinary DNP excretion
(UDNPV; B). Abbreviations are: Baseline, base-
line 30-minute clearance; DNP-10, 30-minute
clearance with 10 ng/kg intravenous infusion
of DNP; DNP-50, 30-minute clearance with 50
ng/kg intravenous infusion of DNP; Recovery,
30-minute clearance after a 150-minute wash-
out period. Repeated-measures analysis of
variance followed by post hoc Bonferroni test
was used for statistical comparisons between
clearances. *P , 0.05 vs. Baseline; † P , 0.05
vs. DNP-10; ‡ P , 0.05 vs. DNP-50.
significant increase in UV. These natriuretic and diuretic properties in normal dogs and that DNP-LI is present
responses to high-dose DNP (DNP-50 clearance) were in canine plasma, urine, and atrial myocardium. DNP-
also associated with increases in plasma cGMP and mediated natriuresis and diuresis were associated with
UcGMPV compared with baseline and with the previous parallel increases in plasma cGMP and urinary cGMP
clearance (DNP-10 clearance). Following DNP infusion, excretion independent of increases in plasma ANP, BNP,
UNaV and UV decreased to the baseline values. These or CNP. Finally, the excretory responses to exogenous
decreases were accompanied by decreases in plasma DNP administration were associated with decreases in
cGMP and UcGMPV. distal tubular reabsorption of sodium and arterial pres-
Table 1 reports the mean arterial pressure (MAP) and sure in the absence of alterations in GFR or RBF.
renal function effects of exogenous DNP. Low-dose DNP Similar to the renal responses to ANP and BNP [15,
increased fractional sodium excretion (FENa) and de- 16], DNP increased urinary cGMP excretion and de-
creased distal fractional reabsorption of sodium (DFRNa). creased distal tubular reabsorption of sodium. These ob-
MAP, GFR, and RBF were unchanged. High-dose DNP
servations support the conclusion that DNP may functiondecreased MAP in association with a further increase in
through the NPR-A receptor, which is linked to particu-FENa and decrease in DFRNa without changes in GFR or late guanylyl cyclase and cGMP generation and is alsoRBF. During the recovery period, MAP returned to near
highly expressed in inner medullary collecting duct cellsbaseline levels with a decrease in RBF. GFR remained
[15]. Such a conclusion is also supported by the reportunchanged during the experiment, whereas DFRNa in-
that DNP displaces ANP binding in vascular smoothcreased to baseline levels during recovery period. Proxi-
muscle cells [9]. We cannot, however, exclude the exis-mal fractional reabsorption of sodium tended to decrease
tence of a new, yet to be identified natriuretic peptideduring DNP administration (PFRNa at baseline, 63 6 6;
receptor. In addition, the lack of increase in plasma ANP,low-dose DNP, 58 6 7; high-dose DNP, 58 6 4; recovery,
BNP, and CNP in this study during DNP administration72 6 6%) but did not reach a significant level. Plasma
also suggests that the renal actions of DNP are directANP, BNP, or CNP did not increase during or after
and not mediated by the other natriuretic peptides. InDNP administration (Table 2).
Atrial myocardial presence of DNP immunoreactivity response to high-dose DNP, MAP decreased and re-
was determined by measurement of tissue DNP concen- turned to near baseline following discontinuation of
tration in normal dogs not exposed to exogenous DNP DNP administration. Such hypotensive action is shared
administration. Atrial tissue concentrations of DNP were by the other natriuretic peptides, which is secondary to
detectable at a concentration of 1950 6 197 pg/g of wet decreases in both cardiac preload and afterload [17–19].
tissue. DNP-LI was also present in atrial myocardium In this study, we cannot exclude that DNP may also
of these dogs using immunohistochemical studies (Fig. enhance sodium excretion by increasing the medullary
4). DNP immunoreactivity was located in the perinuclear blood flow. The decrease in RBF observed during the
region of canine atrial myocytes. recovery period, which followed a 150-minute washout,
may reflect responses to intravascular volume contrac-
DISCUSSION tion following natriuresis and diuresis. An additional
explanation could be a similarity to the intrarenal actionsThis study demonstrates for the first time, to our
knowledge, that DNP has potent natriuretic and diuretic of ANP, which were initially reported to be associated
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Fig. 3. Humoral and renal responses to Den-
droaspis natriuretic peptide (DNP) adminis-
tration. Abbreviations are: Baseline, baseline
30-minute clearance; DNP-10, 30-minute clear-
ance with 10 ng/kg intravenous infusion of
DNP; DNP-50, 30-minute clearance with 50
ng/kg intravenous infusion of DNP; Recovery,
30-minute clearance after a 150-minute wash-
out period. A repeated measures analysis of
variance followed by post hoc Bonferroni test
was used for statistical comparisons between
clearances. *P , 0.05 vs. Baseline; † P , 0.05
vs. DNP-10; ‡ P , 0.05 vs. DNP-50.
Table 2. Plasma natriuretic peptides during DNP administrationTable 1. Dendroaspis natriuretic peptide (DNP)-mediated changes
in renal function
Baseline DNP-10 DNP-50 Recovery
Baseline DNP-10 DNP-50 Recovery
ANP pg /ml 17.460.7 17.6 60.4 18.1 61.2 16.160.6
BNP pg /ml 10.161.4 12.9 62.6 12.6 62.0 9.662.3MAP mm Hg 14166 12868 10967ab 13268
GFR ml/min 3762 4164 3962 26 67 CNP pg /ml 9.760.5 9.1 60.5 9.5 60.9 9.860.8
RBF ml/min 303617 279621 276643 220 632 Abbreviations are: Baseline, baseline 30-min clearance; DNP-10, 30-min clear-
FENa % 1.260.5 2.961.0a 3.960.9a 1.260.4 ance with 10 ng/kg i.v. infusion of DNP; DNP-50, 30-min clearance with 50 ng/kg
DFRNa % 9761 9462a 9162a 9561 i.v. infusion of DNP; Recovery, 30-min clearance after 150-min washout period;
ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CNP, C-typeAbbreviations are: Baseline, baseline 30-min clearance; DNP-10, 30-min clear-
natriuretic peptide. Values are expressed as means 6 standard errors.ance with 10 ng/kg i.v. infusion of DNP; DNP-50, 30-min clearance with 50 ng/kg
i.v. infusion of DNP; Recovery, 30-min clearance after 150-min washout period;
MAP, mean arterial pressure; GFR, glomerular filtration rate; RBF, renal blood
flor; FENa, fractional sodium excretion; DFRNa, distal fractional sodium reabsorp-
tion. Values are expressed as means 6 standard errors.
a P , 0.05 vs. Baseline this previous report and extends the report in humans to
b P , 0.05 vs. DNP-10
a nonhuman mammalian species. Specifically, we report
DNP-LI presence in canine plasma, urine, and atrial
myocardium employing radioimmunoassay and immu-
nohistochemical methods, which possess no cross-reac-with a transient renal vasodilation followed by renal va-
tivity to the other known natriuretic peptides.soconstriction [4, 20].
Further studies are clearly required specifically toWe chose two different doses for DNP to establish a
identify the DNP gene and to determine precise speciesbroad range of plasma concentrations. Importantly, the
amino acid sequences for DNP. Future studies em-lower dose achieved circulating concentrations of approxi-
ploying acute and chronic increases in cardiac filling pres-mately 250 pg/ml, which we now know are at the upper
sures as well as DNP antibodies will be needed to addressrange of those observed in human heart failure and thus
release mechanisms for endogenous DNP, as well as themay be considered pathophysiological. The higher dose
physiological role of DNP in sodium homeostasis. Theseclearly establishes the pharmacological actions of syn-
studies are beyond the scope of this study, which defined,thetic DNP by achieving concentrations of approximately
to our knowledge for the first time, the renal actions of3000 pg/ml. Although the high dose represents pharma-
synthetic DNP.cological actions, the observed renal responses provide
In summary, we report that intravenous administra-insight into the potential therapeutic utility of DNP.
tion of synthetic DNP results in natriuresis and diuresisIn a recent study, our group reported the presence of
in normal dogs and that DNP-LI is present in canineDNP-LI in human plasma and atrial myocardium, with
plasma, urine, and atrial myocardium. This natriuresiselevated concentrations in plasma in humans with con-
gestive heart failure [12]. This study importantly confirms and diuresis is associated with activation of the cGMP
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Fig. 4. Immunohistochemical staining for DNP-like peptide in the canine atrium. Representative sample of atrial myocardium from 10 normal
dogs not exposed to exogenous DNP. NGS means normal goat serum (original magnification, 3400).
sodium; RBF, renal blood flow; RIA, radioimmunoassay; UcGMPV, uri-system and is localized to the terminal nephron indepen-
nary cGMP excretion; UNaV, urinary sodium excretion; UV, urine flow.dent of changes in GFR, RBF, or plasma concentrations
of ANP, BNP, or CNP.
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